Calidi Biotherapeutics, Inc. (CLDI) Stock Score, Valuation & Financial Research

Calidi Biotherapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CLDI

Calidi Biotherapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.07. These figures are a research snapshot, not a buy or sell recommendation.

What Calidi Biotherapeutics, Inc. does

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Calidi Biotherapeutics is a clinical-stage biotechnology company that generates no revenue from product sales as it is currently in the research and development phase. The company focuses on developing proprietary platforms, such as RedTail, to deliver genetic medicines and oncolytic viruses to treat cancer, relying on capital raises and financing activities to fund its operations.

Products and services

  • The company develops targeted immuno-oncology therapies, specifically its proprietary RedTail platform, which uses engineered enveloped oncolytic viruses to deliver genetic payloads to metastatic tumor sites.

Customer types

Clinical trial sites; Healthcare providers.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct preclinical and clinical trials. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes third-party contract manufacturing organizations for the production of its clinical trial materials. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — The company competes with various entities developing oncolytic virus therapies and other immuno-oncology treatments. Source

Business strengths to evaluate

  • Proprietary RedTail platform technology Source
  • Intellectual property portfolio covering delivery systems Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Uncertainty of clinical trial success and regulatory approval Source
  • Reliance on third-party manufacturers and research organizations Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CLDI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.07
Market capitalization:
2.77M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -17.47M
Free cash flow:
USD -21.41M
Cash:
USD 4.07M
Total debt:
USD 1.94M
EPS:
USD -54.14

What stands out

  • Free cash flow is USD -21.41M, negative for the stored period.
  • The balance sheet shows USD 4.07M of cash versus USD 1.94M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.13M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CLDI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CLDI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CLDI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CLDI to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CLDI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CLDI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.